15.468 articles found

Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson's disease pathogenesis.

Senkevich K, Liu L, Alvarado CX, Leonard HL, Nalls MA, Global Parkinson’s Genetics Program (GP2), Gan-Or Z.

NPJ Parkinsons Dis · 2024-08-05

DOI: 10.1038/s41531-024-00744-9PMID: 39103393

Combining salivary α-synuclein seeding activity and miRNA-29a to distinguish Parkinson's disease and multiple system atrophy.

Luan M, Wei L, Sun Y, Chen J, Jiang Y, Wu W, Li F, Sun W, Zhu L, Wang Z, Deng J.

Parkinsonism Relat Disord · 2024-08-05

DOI: 10.1016/j.parkreldis.2024.107088PMID: 39111257

Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinsons linked-LRRK2 mutant mice

Jaimon E, Lin Y, Tonelli F, Antico O, Alessi DR, Pfeffer SR.

· 2024-08-03

DOI: 10.1101/2024.07.31.606089

Transcriptomics and weighted protein network analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson's Disease.

Zhao Y, Bracher-Smith M, Li Y, Harvey K, Escott-Price V, Lewis PA, Manzoni C.

NPJ Parkinsons Dis · 2024-08-03

DOI: 10.1038/s41531-024-00761-8PMID: 39097579

HSPB6: A lipid-dependent molecular chaperone inhibits α-synuclein aggregation.

Secco V, Tiago T, Staats R, Preet S, Chia S, Vendruscolo M, Carra S.

iScience · 2024-08-03

DOI: 10.1016/j.isci.2024.110657PMID: 39280615

Effective lowering of α-synuclein expression by targeting G-quadruplex structures within the SNCA gene.

Pirota V, Rey F, Esposito L, Fantini V, Pandini C, Maghraby E, Di Gerlando R, Doria F, Mella M, Pansarasa O, Gandellini P, Freccero M, Carelli S, Cereda C.

Int J Biol Macromol · 2024-08-03

DOI: 10.1016/j.ijbiomac.2024.134417PMID: 39098688

Antibody conjugated targeted nanotherapy epigenetically inhibits calpain-mediated mitochondrial dysfunction to attenuate Parkinson's disease.

Biswal L, Sahu VK, Sardoiwala MN, Karmakar S, Choudhury SR.

Carbohydr Polym · 2024-08-03

DOI: 10.1016/j.carbpol.2024.122575PMID: 39245478

GBA-AAV mitigates sleep disruptions and motor deficits in mice with REM sleep behavior disorder.

Chen Y, Xie WY, Xia D, Zhang MT, Sun YR, Duan WX, Shen Y, Wang F, Qu WM, Huang ZL, Liu CF.

NPJ Parkinsons Dis · 2024-08-02

DOI: 10.1038/s41531-024-00756-5PMID: 39095359

Convention vs. Innovation II: Skin biopsy for synuclein inclusions will replace dopamine transporter imaging for Parkinson disease diagnosis.

Rosenthal LS, Phillips O, Mari Z.

Parkinsonism Relat Disord · 2024-08-02

DOI: 10.1016/j.parkreldis.2024.107083PMID: 39112124

Imaging spatial transcriptomics reveals molecular patterns of vulnerability to pathology in a transgenic α-synucleinopathy model

Horan-Portelance L, Iba M, Acri DJ, Gibbs JR, Cookson MR.

· 2024-08-01

DOI: 10.1101/2024.07.31.606032

Antibody conjugated targeted nanotherapy epigenetically inhibits calpain-mediated mitochondrial dysfunction to attenuate Parkinson’s disease

Biswal L, Sahu VK, Sardoiwala MN, Karmakar S, Choudhury SR.

Carbohydrate Polymers. · 2024-08-01

Aptamer binding footprints discriminate α-synuclein fibrillar polymorphs from different synucleinopathies.

Bouvier-Müller A, Fourmy D, Fenyi A, Bousset L, Melki R, Ducongé F.

Nucleic Acids Res · 2024-08-01

DOI: 10.1093/nar/gkae544PMID: 38917326